Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

Atypical Hemolytic Uremic Syndrome Clinical Trial

— aHUS  

Official title:

An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00844545
• Other study ID #: C08-002A
• Secondary ID: BB-IND-11075Eudr
• Status: Completed
• Phase: Phase 2
• First received: February 13, 2009
• Last updated: June 30, 2015
• Start date: May 2009
• Est. completion date: July 2013

Study information

• Verified date: June 2015
• Source: Alexion Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationEuropean Union: European Medicines AgencyCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: July 2013
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Exclusion Criteria:

1. TTP, (defined as ADAMTS-13 activity <5%) from an historical observation (prior to initiation of plasma therapy) or as tested at the screening visit by the central laboratory

2. Malignancy within 5 years of screening

3. Typical HUS (Shiga toxin +)

4. Known HIV infection

5. Identified drug exposure-related HUS.

6. Infection-related HUS

7. HUS related to bone marrow transplant

8. HUS related to vitamin B12 deficiency

9. Renal function status requiring chronic dialysis

10. Patients with a confirmed diagnosis of sepsis

11. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease

12. Pregnancy or lactation

13. Unresolved meningococcal disease

14. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome

15. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study

16. Patients who have received previous treatment with eculizumab

17. Patients receiving IVIG within 8 weeks or Rituximab therapy within 12 weeks of screening.

18. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors or tacrolimus are excluded unless: [1] part of an established post-transplant anti-rejection regime, [2] patient has confirmed anti-CFH antibody requiring immunosuppressive therapy, and [3] dose of such medications have been unchanged for at least 4 weeks prior to the screening period or [4] patient is experiencing an acute aHUS relapse immediately after transplant

19. Patients receiving Erythrocyte Stimulating Agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period, or a washout period of at least 2 weeks from the last dose of ESA therapy.

20. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior to screening and throughout the entire trial.

21. Hypersensitivity to eculizumab, to murine proteins or to one of the excipients

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atypical Hemolytic Uremic Syndrome
• Azotemia
• Hemolysis
• Hemolytic-Uremic Syndrome

Intervention

Drug:
• Eculizumab
All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Alexion Pharmaceuticals

Countries where clinical trial is conducted

United States,  Austria,  France,  Germany,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Platelet Count Change From Baseline to 26 Weeks		From Baseline to 26 weeks	No
Primary	Percentage of Patients With Platelet Count Normalization	The primary objective of the study (per protocol) was to assess the effect of eculizumab to reduce TMA as measured by platelet count change from baseline (BL) during the Treatment Period (26 weeks) in patients with plasma therapy (PT)-resistant aHUS (protocol defined), including assessment of the proportion of patients who achieved Platelet Count Normalization from baseline through 26 weeks. Platelet Count Normalization was defined as the platelet count observed to be =150 x 10^9/L on at least two consecutive measurements which span a period of at least four weeks.	Through 26 weeks	No
Primary	Percentage of Patients With Hematologic Normalization	Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.	Through 26 weeks	No
Secondary	Percentage of Patients With Complete TMA Response	The proportion of patients who achieved a Complete TMA Response from baseline through 26 weeks of treatment with eculizumab was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as as =25% reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.	Through 26 weeks	No
Secondary	TMA Intervention Rate	TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through 26 weeks) for PE/PI and (from the fifteenth day following the first eculizumab dose through 26 weeks) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.	Through 26 weeks	No
Secondary	Platelet Count Change From Baseline to 156 Weeks		From Baseline to 156 Weeks	No
Secondary	Percentage of Patients With Platelet Count Normalization	Platelet Count Normalization was defined as the platelet count observed to be =150 x 10^9/L on at least two consecutive measurements which span a period of at least four weeks.	Through End of Study, Median Exposure 100.29 Weeks	No
Secondary	Percentage of Patients With Hematologic Normalization	Hematologic Normalization was defined as normalization of both platelet count and lactic dehydrogenase (LDH) sustained for at least two consecutive measurements which spanned a period of at least four weeks.	Through End of Study, Median Exposure 100.29 Weeks	No
Secondary	Percentage of Patients With Complete TMA Response	The proportion of patients who achieved a Complete TMA Response from baseline through end of the study was determined. Complete TMA Response was defined as Hematologic Normalization plus improvement in renal function (defined as =25% reduction from baseline in serum creatinine), which was sustained for two consecutive measurements over a period of at least four weeks.	Through End of Study, Median Exposure 100.29 Weeks	No
Secondary	TMA Intervention Rate	TMA Intervention Rate (# PE/PI and # Dialysis Events/Patient/Day) in the eculizumab treatment period (from baseline through end of the study) for PE/PI and (from the fifteenth day following the first eculizumab dose through end of the study) for new dialysis events was compared with the TMA Intervention Rate during the pre-eculizumab treatment period.	Through End of Study, Median Exposure 100.29 Weeks	No
Secondary	Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration		Induction Phase for 4 weeks followed by Maintenance Phase starting on Week 5 through 26 weeks or longer.	No